Skip to main content

Table 4 Treatment and survival of the 13 patients with IgD subtype MM

From: Poor outcomes of immunoglobulin D multiple myeloma patients in the era of novel agents: a single-center experience

Patient no. ISS stage Sex Age (years) Introduction therapy/cycles Response Therapy after PD/cycles Survival status PFS (months) OS (months)
1 III Male 51 CTD/5 CR RAD/6 Alive 6.0 17.6
2 III Female 53 CTD/7 PR RD/8 Alive 8.0 19.5
3 III Male 64 VCD/1 PD NA Dead 0.7 0.9
4 III Male 48 VTD/8 PR RCD Dead 26.2 44.3
5 III Female 59 VTD/2 SD NA Dead 5.1 5.7
6 III Male 44 VCD/9 CR TAD/6 + RAD/6 Alive 42.3 47.0
7 III Female 49 VTD/9 CR RAD/10 Dead 28.0 42.6
8 III Male 52 VCD/9 VGPR RD/6 Dead 8.5 13.0
9 III Male 45 VCD/2 CR CTD/8 Alive 2.4 9.2
10 III Male 59 VD/4 PR VCTD/5 Dead 16.7 16.7
11 III Male 51 CTD/5 PR RAD/3 Dead 10.0 6.6
12 III Female 56 VCD/4 + ASCT VGPR CTD/4 Dead 18.7 22.9
13 III Female 66 VD/4 VGPR RD/6 Dead 48.0 66.0
  1. IgD immunoglobulin D, ISS international staging system, PD progressive disease, PFS progression-free survival, OS overall survival, CTD thalidomide + cyclophosphamide + dexamethasone, CR complete response, RAD lenalidomide + adriamycin + dexamethasone, PR partial response, RD lenalidomide + dexamethasone, VCD bortezomib + cyclophosphamide + dexamethasone, PD progressive disease, NA not applicable, VTD bortezomib + thalidomide + dexamethasone, RCD lenalidomide + cyclophosphamide + dexamethasone, SD stable disease, TAD thalidomide + adriamycin + dexamethasone, VGPR very good partial response, VD bortezomib + dexamethasone, VCTD bortezomib + thalidomide + cyclophosphamide + dexamethasone, ASCT autologous stem cell transplantation